Indivior Presents Positive Top-line Phase 3 Pivotal Study Results for RBP-6000 Buprenorphine Monthly Depot

Indivior provided positive top-line results of the pivotal Phase 3 clinical trial of investigational drug, RBP-6000 buprenorphine monthly depot, for the treatment of opioid use disorder to be used in conjunction with counseling and psychosocial support.

RBP-6000 is a subcutaneous long-acting monthly depot injection that delivers a sustained-release formulation of buprenorphine.

The primary objective of this study was to assess the efficacy of monthly SC injections of RBP-6000.

The drug has yet to receive FDA market approval.